Title:
The monoclonal antibody to Claudin 18 for the medical treatment of cancer
Document Type and Number:
Japanese Patent JP6261650
Kind Code:
B2
Abstract:
The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.
More Like This:
| WO/2007/089690 | TAT-042 AND METHODS OF ASSESSING AND TREATING CANCER |
| WO/2021/259101 | ANTI-HER2 MONOCLONAL ANTIBODY LYOPHILIZED PREPARATION AND PREPARATION METHOD |
| WO/2018/014864 | BISPECIFIC ANTI-HER2 ANTIBODY |
Inventors:
Sahin, Uguru
Thulech, Ezrem
Usener, Dark
Fritz, Stefan
Uchelek, Christoph
Brandenburg, Gunda
Geppert, Harald Gerhard
Sheroder, Anya Christina
Teal, Philip
Thulech, Ezrem
Usener, Dark
Fritz, Stefan
Uchelek, Christoph
Brandenburg, Gunda
Geppert, Harald Gerhard
Sheroder, Anya Christina
Teal, Philip
Application Number:
JP2016098892A
Publication Date:
January 17, 2018
Filing Date:
May 17, 2016
Export Citation:
Assignee:
Ganymed Pharmaceuticals Game Behr
International Classes:
C07K16/30; C07K19/00; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/09; C12P21/08
Foreign References:
| WO2004047863A1 | ||||
| WO2004029207A1 |
Other References:
Shinkawa T et al,The Journal of Biological Chemistry,2003年 1月31日,Vol. 278, No. 5,p. 3466-3473
Attorney, Agent or Firm:
Shinji Hayami